As of October 12, 2026, none of the six peptides that received favorable advisory votes from the FDA’s Pharmacy Compounding Advisory Committee (PCAC) in July 2026 have been formally added to the 503A Bulk Drugs List in 21 CFR 216.23. The peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — remain in regulatory limbo despite the committee’s support.
The PCAC votes, which took place July 23–24, 2026, are advisory only. Formal addition to the 503A Bulk Drugs List requires notice-and-comment rulemaking, a process FDA has not yet initiated for any of the six substances. The agency has not published a timeline for doing so.
The delay leaves 503A compounding pharmacies, telehealth platforms, and patients who have been using these compounds in a state of ongoing regulatory ambiguity.
What happened
On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee held a meeting at which it voted favorably on six peptide bulk drug nominations for potential inclusion on the 503A Bulk Drugs List. The six peptides were BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon.
However, advisory committee votes do not themselves change federal regulation. To add a substance to the 503A Bulk Drugs List codified at 21 CFR 216.23, FDA must conduct notice-and-comment rulemaking — a formal process involving a proposed rule, a public comment period, and a final rule. As of October 12, 2026, no such rulemaking has been initiated for any of the six peptides, and FDA has not indicated when it might begin.
Why it matters
Under federal law, 503A compounding pharmacies may only compound drugs using bulk drug substances that appear on the FDA’s 503A Bulk Drugs List. Because none of the six peptides have been added to that list, 503A pharmacies currently have no federal legal pathway to lawfully compound these substances — even though an FDA advisory committee has voted in their favor.
This creates practical uncertainty across several groups:
- 503A compounding pharmacies — no clear federal legal pathway to compound these six peptides while rulemaking remains pending.
- Telehealth peptide platforms — ongoing regulatory ambiguity about whether these compounds can be prescribed and dispensed through 503A channels.
- Patients using BPC-157, TB-500, KPV, MOTS-c, Semax, or Epitalon — continued uncertainty about access and legal status.
- Peptide research buyers — demand persists without clear federal regulatory status for these substances.
The absence of any published timeline from FDA leaves affected parties unable to plan with confidence regarding when, or whether, these substances may be formally added to the 503A list.
What to watch next
- Whether FDA initiates notice-and-comment rulemaking for any or all of the six peptides in the coming months.
- Whether FDA publishes a timeline or guidance addressing the status of these substances during the interim period.
- Whether any 503A pharmacies or telehealth platforms adjust their compounding practices in response to the regulatory uncertainty.
- Whether any stakeholders petition FDA or take other steps to accelerate the rulemaking process.
Sources
- MDside — Peptide Advisory Vote: What Happens Next
- InsidePeptides.org — HHS Plan to Allow Temporary Sales of Unapproved Peptides
Industry information only. Not medical or legal advice.
